StockpollyBeta
Get App
Popularity #2,613
NGNE · NASDAQ · Biotechnology

Neurogene (NGNE)

Builds a single gene therapy for Rett syndrome using a proprietary expression-control platform.

$33.60
After hours+0.02 (+0.06%)
At close$33.58(+3.10%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000100000000
Cost of revenue012111615181917110
Gross profit0−12−10−16−15−18−19−17−1−10
153182066877273237
Research & development121214161615181917212525
4345668776811
Selling & marketing00−1000000000
General & administrative4355668770811
Other expenses0−120−1−16−15−18−19−170−10
Operating income−15−15−19−20−22−22−26−26−24−28−33−37
1172222343322
Interest income112222333322
Interest expense000000000000
Other non-operating income−1−17−2−2−2−2−3−4−3−3−2−2
Income before tax−152−17−18−20−20−23−22−21−25−31−34
Net income from continuing operations−152−17−18−20−20−23−22−21−25−31−34
Net income−152−17−18−20−20−23−22−21−25−31−34
EPS, basic−$0.41$4.08−$1.00−$1.09−$1.19−$1.31−$1.08−$1.05−$0.99−$1.60−$1.39−$1.53
EPS, diluted−$0.41$4.08−$1.00−$1.09−$1.19−$1.31−$1.08−$1.05−$0.99−$1.60−$1.39−$1.53
Weighted average shares, basic111317171715212121152223
Weighted average shares, diluted111317171715212121152223
EBITDA−143−16−18−19−19−22−21−20−24−30−32
Depreciation & amortization111111111112
EBIT−152−17−18−20−20−23−22−21−25−31−34